- Design
- Scoping review of 48 reports (interventional studies, case reports, reviews)
- Population
- Adults taking a beta-blocker and an SSRI together
- Primary outcome
- Reported adverse events of the combination
- Effect
- Bradycardia most frequent (11 reports), mainly metoprolol or propranolol with fluoxetine, paroxetine or sertraline
A scoping review in the British Journal of Clinical Pharmacology (7 October) gathered 48 reports, mostly interventional studies and case reports, of adverse events when beta-blockers and SSRIs were taken together.
Bradycardia was the commonest event, reported mainly with metoprolol or propranolol combined with fluoxetine, paroxetine or sertraline. Blood pressure changes, including hypotension, appeared in half of studies that looked for them. Where a mechanism was proposed, it was usually inhibition of CYP2D6 by the SSRI raising beta-blocker levels.
The evidence measures nothing precisely, but the pharmacology is consistent and the choice is easy. Metoprolol and propranolol depend on CYP2D6; fluoxetine and paroxetine are strong CYP2D6 inhibitors. Where both drug classes are needed — anxiety with palpitations, depression after a heart attack — choosing a beta-blocker less dependent on CYP2D6, or an SSRI with weaker CYP2D6 inhibition, avoids the issue.
- Avoid pairing metoprolol or propranolol with fluoxetine or paroxetine where an alternative exists
- Consider a beta-blocker less dependent on CYP2D6, such as bisoprolol or atenolol
- Or consider an SSRI with weaker CYP2D6 inhibition, such as citalopram or escitalopram
- Check heart rate and blood pressure after starting or increasing either drug
- Remember fluoxetine's long half-life: the interaction can persist for weeks after stopping
Why it matters
A common combination carries a predictable interaction that is avoided by choosing the right partners.
Don't overread it
Mostly case reports — the review signals a risk but cannot say how often it occurs.
The statistics, in plain English
A scoping review maps what has been reported; it does not pool data or estimate risk. The value here is in the consistency of the drug pairs involved, not in any number.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free